Asit biotech has finished the second phase of testing an allergen for treating problems caused by in house dust mite-induced rhinoconjunctivitis.
According to the company, Professor Bettina Hauswald with his team took a double-blind placebo-controlled clinical trial in house dust mite rhinitis at the Carl Gustav Carus University Hospital in Dresden, Germany. Of the 37 patients who participated in the treatment with hdm-ASIT+, 33 attended the last visit to the allergist, giving a retention rate of 89%, the company further said in its press release.
Asit biotech is currently cleaning the clinical database. After that, it will publish the results by the end of the first quarter of 2017.
Thierry Legon, CEO of ASIT biotech, said that 89% retention rate means that the drug candidate hdm-AIST+ is safe and well tolerated even at high allergen doses.